ARNOLD & PORTER LLP

A Solve of the second

202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206

December 2, 2004

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Rē:

U.S. Application No. 09/338,063

Filed: June 23, 1999

Title: Monoclonal Antibodies that Bind OCIF (as amended)

Applicants: GOTO *et al.* Atty. Docket: 16991.005

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

- 1. a Summary of Examiner Interview; and
- 2. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

In the event that extensions of time beyond those petitioned for herewith are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number 16991.005. A duplicate copy of this letter is enclosed.

Respectfully submitted,

David R. Marsh (Reg. Attorney No. 41,408)

istom Lansten

Kristan L. Lansbery (Reg. Agent No. 53,183)

Enclosures



In re Patent Application of:

GOTO et al.

Appln. No.: 09/338,063

Filed: June 23, 1999

For: Monoclonal Antibodies that Bind

OCIF

Art Unit: 1644

Examiner: G. Ewoldt

Atty. Docket: 16991.005

Confirmation No.: 9916

Summary of Examiner Interview

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In a telephone interview with Examiner Gerald R. Ewoldt, Ph.D. on November 29, 2004, the Examiner stated that the substitute specification, filed on November 12, 2003, should be entered. Applicants agree with the decision to enter the substitute specification and understand that the other items filed on November 13, 2004, including a substitute sequence listing, will also be entered. If this understanding is not correct, Applicants respectfully request notification. The Notice of Allowability, mailed on March 1, 2004, was responsive to Applicants' October 14, 2003 filing, despite the intervening submission of, *inter alia*, the substitute specification on November 12, 2003.

Applicants note that in the Response to Rule 312 Communication, mailed on March 27, 2002, the Office indicated that the amendment would be entered in part. Applicants did not receive the Response to Rule 312 Communication until after the issue fee for the above-identified application was paid on July 1, 2004, the due date. In order to expedite issuance,

Application No. 09/338,063 GOTO et al.

Page 2

Applicants will not pursue the amendments requested, but not entered, in the Amendment After

Allowance, filed on March 10, 2004. Applicants reserve the right to pursue the amendments in

the Amendment After Allowance in priority applications and continuing applications without

prejudice.

Should the Examiner have any questions regarding the above-identified application or if

the Applicants are wrong to believe that the subject matter of the November 13, 2004 filing was

entered, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

David R. Marsh (Reg. Attorney No. 41,408)

Kristan L. Lansbery (Reg. Agent No. 53,183)

Date: December 2, 2004

ARNOLD & PORTER 555 Twelfth Street, N.W.

Washington, D.C. 20004-1206

(202) 942-5186 telephone

(202) 942-5999 facsimile